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Abstract
Background: One-lung ventilation during thoracic surgery frequently disturbs normal systemic oxygenation. However,
the effect of anesthetics on arterial oxygenation during one-lung ventilation has not been well established in human
study. In this clinical trial, we investigated whether a difference between desflurane-remifentanil and propofol-remifentanil
anesthesia can be observed with regard to oxygenation during one-lung ventilation for thoracoscopic surgery.
Methods: Adult patients with lung cancer, scheduled for video-assisted thoracoscopic lobectomy without preoperative
oxygen support, were screened and randomized to receive desflurane or propofol, with remifentanil continuous infusion
in both groups. Mechanical ventilation was performed with tidal volume of 8 ml/kg and FIO2 0.5 during two-lung
ventilation, and 6 ml/kg and 1.0 during one-lung ventilation, both with positive end-expiratory pressure of 5 cmH2O.
Arterial blood gas analysis was performed preoperatively, during two-lung ventilation, and after 15, 30, 45, and 60 min of
one-lung ventilation. The primary endpoint was PaO2 at 30 min after initiating one-lung ventilation. Statistical analyses
included the independent t-test for the primary endpoint and a mixed model with a post-hoc analysis to evaluate the
serial changes in values.
Results: Patients were recruited between July 9 and December 2, 2014. In total, 103 patients were analyzed (n = 52 in
desflurane group and n= 51 in propofol group). The primary endpoint, PaO2 at 30 min of one-lung ventilation was lower
in the desflurane group than the propofol group (170 ± 72 vs. 202 ± 82 mmHg; p = 0.039). Serial changes in PaO2 during
one-lung ventilation showed lower levels during desflurane anesthesia compared with propofol anesthesia (mean
difference, 45 mmHg; 95% confidence interval, 16–75 mmHg; p= 0.003).
Conclusions: In conclusion, desflurane-remifentanil anesthesia resulted in decreased arterial oxygenation compared with
that of propofol-remifentanil anesthesia during one-lung ventilation for thoracoscopic surgery in patients with lung
cancer.
Trial registration: ClinicalTrials.gov identifier: NCT02191371, registered on July 7, 2014
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Background
One-lung ventilation (OLV) during thoracic surgery can
rapidly result in impaired systemic oxygenation. The grade
of hypoxemia during OLV is mainly influenced by an in-
crease in shunt and dead space. Hypoxic pulmonary vaso-
constriction (HPV) is a physiological protective mechanism
that diverts pulmonary perfusion from the non-ventilated
to the ventilated area of the lung, thereby decreasing the
shunt of unsaturated blood and ameliorating the degree of
hypoxemia. This physiologic modulation is influenced by
numerous factors such as various drugs, temperature, acid–
base status, airway pressure, patient position, and cardiac
output [1]. In numerous animal studies and in studies of
isolated lungs, HPV has been shown to be modulated by
volatile anesthetics [1–5]. However, human studies have
yielded inconsistent results regarding the effects of different
anesthetics on systemic oxygenation during OLV [6–10].
Moreover, the effects of desflurane-remifentanil balanced
anesthesia have not been evaluated in a clinical study.
Most halogenated inhaled anesthetics are character-
ized by its dose-dependent systemic vasodilatory effect
[11–14]. We hypothesized that the vasodilatory effect of
desflurane may affect any protective role of HPV, thus
impair oxygenation during OLV, even when it is used as
a balanced anesthesia, compared with total intravenous
anesthesia (TIVA). To evaluate this hypothesis, we com-
pared the effects of two commonly used modern anes-
thetics, desflurane and propofol, with concomitant
remifentanil continuous infusion in both arms, on sys-
temic oxygenation during OLV for video-assisted thora-
coscopic surgery.
Methods
The Institutional Review Board of Seoul National Univer-
sity Hospital approved this study (reference # 1406-052-
587; approval date, July 7, 2014). All patients provided
written informed consent, and the study was performed ac-
cording to Good Clinical Practice guidelines and the princi-
ples of the Declaration of Helsinki (ClinicalTrials.gov
identifier: NCT02191371; principal investigator, Yunseok
Jeon; registered on July 7, 2014).
Patient inclusion and randomization
Patients with lung cancer scheduled for elective video-
assisted thoracoscopic lobectomy requiring OLV at Seoul
National University Hospital were screened for eligibility.
Exclusion criteria were age < 20 years, ASA class > III,
BMI > 30 kg/m2, symptomatic or severe obstructive or re-
strictive lung disease, requirement for preoperative oxygen
supply, preoperative intubated state or under mechanical
ventilatory support, baseline arterial partial pressure of
oxygen (PaO2) < 70 mmHg, symptomatic coronary or
peripheral arterial disease, renal failure, preoperative con-
tinuous infusion of inotropes or vasopressor, refuse to
participate in the study, and pregnancy. The interpretation
of the pulmonary function test results was based on the
American Thoracic Society/European Respiratory Society
guidelines [15]. Obstructive disease was defined when
forced expiratory volume in 1 s (FEV1)/forced vital cap-
acity (FVC) was < 0.7, and severity was determined by %
predicted FEV1 value; severe disease was diagnosed when
FEV1 < 50% predicted value.
After receiving informed consent, eligible patients were
randomized to receive either inhalational anesthesia with
desflurane (Suprane®, Baxter Healthcare, Deerfield, IL) or
intravenous anesthesia with propofol (Fresofol®2 MCT 2%,
Fresenius Kabi, Graz, Austria) as a main anesthetic, in the
morning of the day of surgery. Block randomization
(blocks of 4 or 6) was performed before assigning the
groups using a computer-generated randomization pro-
gram operated by a clinician not involved in the study.
Baseline pulmonary function, blood pressure and heart
rate were recorded one day before surgery.
Study protocol
Standardized pre-surgical and surgical procedures were
described previously [16]. Three-lead electrocardiog-
raphy, pulse oximetry (SpO2), and non-invasive blood
pressure monitoring were performed in all patients.
Without premedication, general anesthesia was induced
with target-controlled infusion of propofol (starting with
a target effect site concentration, Ce of 4 μg/ml) in the
propofol group. In the desflurane group, we avoided the
use of propofol even during the induction period. There-
fore, we used etomidate (Etomidate® Lipuro, 0.25 mg/kg;
B. Braun, Melsungen, Germany) to induce anesthesia to
exclude any potential effects of propofol in the desflur-
ane group. Anesthesia was maintained with either des-
flurane (5–7 vol%) or propofol (Ce of 3–4 μg/ml), and
all patients were continuously infused with remifentanil
(Ce of 1.5–3.5 ng/ml, Ultiva™; GlaxoSmithKline, San
Polo di-Torrile, Italy) during anesthesia induction and
throughout the surgery. Administration of anesthetics
(desflurane or propofol) was titrated to maintain appro-
priate anesthetic depth [bispectral index (BIS), 30–50]
using electroencephalogram-based hypnotic monitor
(BIS VISTA™ monitor, Aspect Medical Systems, Nor-
wood, MA). In both groups, infusion of remifentanil was
adjusted according to hemodynamic changes. A com-
mercial infusion pump (Orchestra®; Fresenius Vial, Bre-
zins, France) was used for target-controlled infusion of
propofol and remifentanil according to the patients’
demographic data (sex, age, height and weight). The
techniques for anesthesia maintenance in our study were
based on those described in previous studies and text-
books [17–20]. Infusion of propofol was monitored with
the Marsh pharmacokinetic model and remifentanil with
the Minto model.
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After establishing neuromuscular blockade with admin-
istration of rocuronium (0.6–0.8 mg/kg), the patient’s tra-
chea was intubated with a left or right double-lumen
endotracheal tube (Mallinckrodt™ endobronchial tube, size
32–39 Fr; Covidien, Mansfield, MA). The size of the tube
was chosen based on the patient’s height and mainstem
bronchial diameter, and the correct position of the tube
was confirmed with a flexible fiber-optic bronchoscope.
The lungs were mechanically ventilated with volume-
controlled ventilation with a tidal volume of 8 ml/kg (pre-
dicted body weight, PBW) during two-lung ventilation
(TLV) and 6 ml/kg (PBW) during OLV. The inspired oxy-
gen fraction (FIO2) was set to 0.5 during TLV and 1.0 dur-
ing OLV. After the patients were positioned in the lateral
decubitus position, the endotracheal tube position was
rechecked using a fiber-optic bronchoscope before initi-
ation of OLV. Respiratory rate was started at 12/min and
adjusted to maintain a carbon dioxide arterial partial pres-
sure of between 35 and 45 mmHg. Positive end-expiratory
pressure was maintained at 5 cmH2O.
The right or left radial artery was cannulated with a 20-G
Angiocath™ (Becton Dickinson Medical Ltd., Tuas,
Singapore) and connected to a FloTrac™ transducer with an
EV1000™ monitor (Edwards Lifesciences LLC, Irvine, CA).
Arterial blood pressure and cardiac index by pulse-contour
analysis were monitored continuously, and arterial blood
sampling for gas analysis was conducted through the
arterial cannula. A central venous catheter (Multi-Med;
Edwards Lifesciences) was placed at either the right or left
internal jugular vein under ultrasonographic guidance.
Crystalloid or colloid was administered to maintain ad-
equate hemodynamics by the attending anesthesiologist. A
paravertebral and/or intercostal nerve block was performed
at the surgeon’s discretion before the surgery was
completed. Intravenous patient-controlled analgesia with
morphine and fentanyl was provided to all patients postop-
eratively according to their demographic data and the ex-
tent of the surgery.
Data collection
Hemodynamic recording and arterial blood gas analysis
were conducted at the following time points: (1) pre-
operatively, (2) TLV before OLV, (3) 15, (4) 30, (5) 45,
and (6) 60 min after initiation of OLV. Preoperative data
were obtained on room air one day prior to surgery. To
minimize the effect of the patient’s position, data during
TLV were obtained in the lateral decubitus position. Ar-
terial blood gas analysis was performed using a GEM®
Premier 3000 (Model 5700; Instrumentation Laboratory,
Lexington, MA) within 3 min after obtaining the blood
sample. We restricted recruitment maneuvers to the
ventilated lung during OLV, unless there was unaccept-
able desaturation (defined as SpO2 < 90% or PaO2 <
70 mmHg at FIO2 1.0) or difficulty in maintaining OLV
without additional manipulation. If additional manipula-
tion was required, subsequent data were excluded from
the analysis to avoid any confounding effects.
Primary endpoint and power analysis
The primary endpoint was PaO2 at 30 min of OLV. In a
previous study that investigated oxygenation during
OLV in patients receiving propofol, mean ± SD PaO2 at
30 min of OLV was 28 ± 9 kPa (209 ± 68 mmHg) [21].
We calculated that 52 patients would be required per
group to detect a PaO2 difference of 20% after 30 min of
OLV between the groups, as compared using an inde-
pendent t-test, including a 20% dropout rate, using a
two-sided design at a significance level of 5% and 80%
power (G*Power ver. 3.1.9.2; Franz Faul, Universitat Kiel,
Germany).
Statistical analyses
Data are presented as the means ± SD, numbers (%), or
median (95% confidence interval). Normality of the data
was checked using the Kolmogorov–Smirnov and Sha-
piro–Wilk tests. Residuals vs. fitted values plots were
used for repeated-measured variables to check that the
error terms (residuals) had a mean of zero and constant
variance. The plots showed a pattern consistent with
equal variances. The normality assumption for the
model residuals was checked with histograms and nor-
mal quantile-quantile (Q-Q) plots of the residuals, and
the data were determined to be normally distributed.
Comparisons were conducted using the independent t-
test or Mann–Whitney U-test for continuous variables,
and Pearson’s chi-squared test or Fisher’s exact test for
non-continuous variables. Sequential changes of vari-
ables were analysed using linear mixed models with
Bonferroni’s correction. In the mixed model, the treat-
ment group, time, and the interaction between group
and time were regarded as fixed effects, and subject was
regarded as a random effect. Analysis was performed
using SPSS software (ver. 21.0.0.0 for Windows; IBM,
Armonk, NY). In all analysis, p <0.05 was taken to indi-
cate statistical significance.
Results
Patient recruitment and data collection was performed
between July and December 2014. Among the 183 pa-
tients with lung cancer screened for eligibility, 104 pa-
tients were randomized to either desflurane (n = 52) or
propofol group (n = 52; Fig. 1). After completion of
protocol, 103 patients (52 in the desflurane and 51 in
the propofol group) were analyzed. One patient in the
propofol group was excluded from the primary analysis,
as her baseline PaO2 was lower than the exclusion cri-
teria (70 mmHg). The characteristics of the patients in-
cluded in this study were well balanced between the
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groups (Table 1). There was no difference in underlying
diseases and current medications between groups. We
included patients scheduled for a lobectomy at enrol-
ment, but several patients required procedures other
than pre-planned lobectomy during surgery (Table 1).
The distribution of operation types was comparable be-
tween the groups (p = 0.428). The right lung was venti-
lated during OLV in 32/52 and 34/51 patients in the
desflurane and propofol groups, respectively (p = 0.682).
Intraoperative blood gas and anesthetic variables at each
time point in each group are shown in Table 2. Preopera-
tive and pre-OLV (during TLV before initiation of OLV)
PaO2 were comparable between the groups (92 ± 14 vs.
93 ± 11 mmHg and 217 ± 35 vs. 231 ± 60 mmHg in the
desflurane vs. propofol group, respectively). Three pre-
OLV PaO2 data (2 in the propofol group and 1 in the des-
flurane group) were excluded from analysis, as FIO2 (0.5)
was not maintained during the period. The primary
endpoint, PaO2 at 30 min of OLV was lower in the
desflurane group than the propofol group (170 ± 72 vs.
202 ± 82 mmHg in desflurane vs. propofol group, respect-
ively; p = 0.039). For other time points during OLV, PaO2
was lower in the desflurane group compared to the
propofol group [180 ± 75 vs. 226 ± 84 mmHg (p = 0.004),
179 ± 85 vs. 214 ± 82 mmHg (p = 0.043), and 198 ± 90 vs.
258 ± 122 mmHg (p = 0.009) in desflurane vs. propofol
group at 15, 45, and 60 min of OLV, respectively; Fig. 2].
The lowest PaO2 during the OLV period was lower in the
desflurane group than the propofol group (133 ± 50 vs.
162 ± 63 mmHg, respectively; p = 0.010). The serial
changes in PaO2 during 60 min of OLV revealed a lower
PaO2 in the desflurane group compared to that in the pro-
pofol group (mean difference, 45 [95% CI, 16–75] mmHg;
p = 0.003). The interaction between group and time was
not significant during OLV (p = 0.098). Compared to the
pre-OLV state, PaO2 at 15, 30, and 45 min of OLV were
significantly lower in the desflurane group (217 ± 35 vs.
180 ± 75, 170 ± 72, and 179 ± 85 mmHg; adjusted p =
0.003, p < 0.001, and p = 0.002, respectively), but not in the
propofol group at any time point (Fig. 2).
After 30 min of OLV, mean arterial pressure (MAP)
was lower in the desflurane group, and accordingly,
lesser remifentanil was used in the desflurane group
than propofol group (Table 2). The total amounts of
remifentanil administered during surgery were 911 ±
337 μg in the desflurane group and 1407 ± 638 μg in the
Fig. 1 CONSORT diagram of study flow
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propofol group, respectively (p <0.001). BIS was main-
tained within the target range (30–50) throughout the
surgery in both groups.
Two patients in the desflurane group received continuous
infusion of a vasoactive drug (noradrenaline and phenyl-
ephrine, respectively) to maintain adequate hemodynamics.
None of the patients received transfusion peri-operatively.
Three cases in the desflurane group (p = 0.243) required
lung recruitment strategies during OLV to maintain an ad-
equate oxygenation profile, and therefore subsequent data
were excluded from comparison of PaO2 in these patients
after the recruitment maneuvers. The rescue maneuvers
were performed after 30 min of OLV in all three cases.
After alveolar recruitment, hypoxemia was improved and
no changes in the anesthetic protocol were required.
Discussion
In this study, oxygenation under desflurane-remifentanil
balanced anesthesia was lower than that under propofol-
remifentanil TIVA during OLV for video-assisted thora-
coscopic surgery. This is the first reported clinical trial
in which desflurane was shown to impair oxygenation
during OLV compared to TIVA in lung cancer patients
undergoing thoracoscopic lung surgery.
Recently, many surgical procedures have been per-
formed using less-invasive approaches. Large percent-
ages of thoracic operations for lung resection are
performed through video-assisted thoracoscopic surgery.
Thus, the durations of both the operation and postoper-
ative recovery period have been shortened. Both desflur-
ane and propofol are relatively new anesthetics with
short-acting properties characterized by rapid onset and
offset due to their low blood gas partition coefficient
and low context-sensitive half time, respectively. Th-
erefore, they are highly attractive and offer fast-track
Table 1 Characteristics of patients receiving desflurane-
remifentanil or propofol-remifentanil during one-lung ventila-
tion for thoracoscopic surgery
Desflurane
group (n = 52)
Propofol
group (n = 51)
p value
Female 18 (35%) 23 (45%) 0.277
Age (year) 63 ± 8 62 ± 10 0.841
Body mass index
(kg/m2)
24.0 ± 2.8 22.9 ± 2.8 0.050
ASA class 0.914
I 24 (46%) 23 (45%)
II 28 (54%) 28 (55%)
Smoking history 0.257
Never smoker 28 (54%) 28 (55%)
Current smoker 11 (21%) 16 (31%)
Former smoker 13 (25%) 7 (14%)
Preoperative
hemoglobin (g/dl)
13.2 ± 1.3 13.2 ± 1.3 0.820
Preoperative FEV1
(% predicted)
100.6 ± 16.3 103.8 ± 19.0 0.356
Preoperative FVC (%
predicted)
98.0 ± 12.6 100.2 ± 13.7 0.391
Preoperative PaO2
(mmHg)
92 ± 14 93 ± 11 0.798
Preoperative medications
Aspirin 7 (14%) 8 (16%) 0.749
COX inhibitor
other than aspirin
2 (4%) 4 (8%) 0.437
Calcium
antagonist
12 (23%) 11 (22%) 0.854
ACE inhibitor 0 (0%) 1 (2%) 0.495
ARB 10 (20%) 13 (26%) 0.446
Beta blocker 2 (4%) 3 (6%) 0.678
Diuretics 2 (4%) 6 (12%) 0.160
OHA 7 (14%) 9 (18%) 0.558
Clopidogrel 0 (0%) 2 (4%) 0.243
Statin 8 (15%) 14 (28%) 0.135
Steroid 0 (0%) 2 (4%) 0.243
Prostacyclin 0 (0%) 1 (2%) 0.495
Anesthesia time
(min)
222 ± 47 211 ± 46 0.243
Infused crystalloid
(ml)
940 ± 505 784 ± 378 0.079
Infused colloid (ml) 117 ± 192 99 ± 167 0.600
Urinary output (ml) 192 ± 159 201 ± 152 0.769
Estimated blood
loss (ml)
160 ± 89 143 ± 75 0.299
Extent of operation 0.428
Lobectomy 41 (79%) 44 (86%)
Table 1 Characteristics of patients receiving desflurane-
remifentanil or propofol-remifentanil during one-lung ventila-
tion for thoracoscopic surgery (Continued)
Segmentectomy 7 (13%) 3 (6%)




Right upper lobe 16 (31%) 15 (29%)
Right middle
lobe
3 (6%) 7 (14%)
Right lower lobe 13 (25%) 12 (23%)
Left upper lobe 10 (19%) 8 (16%)
Left lower lobe 10 (19%) 9 (18%)
FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, PaO2 arterial
partial pressure of oxygen, COX cyclooxygenase, ACE angiotensin converting
enzyme, ARB angiotensin receptor blocker, OHA oral hypoglycemic agent.
Preoperative FEV1 and FVC are expressed as percentages of the predicted
value. Values are numbers (%) or means (SD)
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anesthesia and earlier recovery for postoperative rehabili-
tation in minimal invasive thoracic surgery. However, the
roles of these modern anesthetics in management of oxy-
genation during OLV remain unclear in humans.
In animal studies, inhalational anesthetics are known
to inhibit the protective role of HPV during alveolar
hypoxia combined with OLV both in vitro and in vivo
[2]. Halothane, enflurane, isoflurane, sevoflurane, and
desflurane depressed HPV in a dose-dependent manner
in isolated rat or rabbit lung [4, 22, 23]. Isoflurane or
desflurane impaired oxygenation during OLV, while
intravenous anesthetics, such as propofol or pentobar-
bital, had no detrimental impact on HPV in animal stud-
ies [3, 5, 24, 25]. However, in clinical investigations,
results regarding the effects of anesthetics on ox-
ygenation and HPV during OLV have been inconsistent
[6–10, 26, 27]. Propofol improved oxygenation and
shunt fraction during OLV compared to sevoflurane
anesthesia in patients undergoing esophagectomy [6] or
thoracotomy pulmonary lobectomy [27]. In other
studies, propofol anesthesia did not differ in changes in
shunt fraction or oxygenation during OLV for thoracic sur-
gery in comparison with sevoflurane or isoflurane [7–10].
Moreover, arterial oxygenation was not different between
propofol-alfentanil vs. isoflurane anesthesia during OLV in
patients undergoing thoracoscopic pulmonary surgery or
esophageal surgery [26]. Above all, there have been no pre-
vious reports comparing the effects of the two commonly
used anesthetics, desflurane and propofol, on arterial oxy-
genation during OLV in thoracic surgical patients.
In accordance with previous reports [21, 28], our data
demonstrated a decrease in PaO2 during the first 30 min
of OLV and gradual improvement thereafter in both
groups (Fig. 2). During desflurane anesthesia, PaO2 de-
creased significantly after 15 min of OLV compared to
the pre-OLV state, and then recovered gradually to pre-
Table 2 Intraoperative blood gas and anesthetic variables in patients receiving desflurane-remifentanil or propofol-remifentanil
during one-lung ventilation
TLV 15 min of OLV 30 min of OLV 45 min of OLV 60 min of OLV
Desflurane group (n = 52)
End-tidal desflurane (vol%) 5.4 ± 1.0 6.2 ± 0.8 6.2 ± 0.8 6.2 ± 0.8 6.2 ± 0.8
Minimum alveolar concentration 1.0 ± 0.2 1.1 ± 0.2 1.1 ± 0.2 1.1 ± 0.1 1.1 ± 0.2
Ce, remifentanil (ng/ml) 2.3 ± 1.1 2.4 ± 0.9* 2.1 ± 1.1* 1.9 ± 1.0* 1.8 ± 1.0*
MAP (mmHg) 84 ± 13 85 ± 15 78 ± 12* 75 ± 12* 78 ± 9*
HR (beats/min) 68 ± 13 67 ± 11 70 ± 11 68 ± 10 69 ± 12
BT (°C) 36.1 ± 0.4 36.1 ± 0.4 36.0 ± 0.4 35.9 ± 0.4 35.8 ± 0.5
CVP (mmHg) 7 ± 3 8 ± 3 7 ± 3 7 ± 3 7 ± 3
CI (l/min/m2) 2.7 ± 0.6 2.6 ± 0.6 2.9 ± 0.7 2.9 ± 0.7 2.9 ± 0.7
Ppeak (cmH2O) 19 ± 2 22 ± 3 23 ± 4 23 ± 3 23 ± 3
PaCO2 (mmHg) 41 ± 4 45 ± 5 45 ± 4 45 ± 4 45 ± 5
Arterial blood pH 7.4 ± 0.0 7.4 ± 0.0 7.4 ± 0.0 7.4 ± 0.0 7.4 ± 0.0
Base excess (mmol/l) 2.1 ± 2.2 1.9 ± 2.1 1.5 ± 2.2 1.6 ± 2.0 1.5 ± 2.1
Propofol group (n = 51)
Ce, propofol (μg/ml) 3.6 ± 0.6 3.6 ± 0.6 3.5 ± 0.5 3.5 ± 0.5 3.6 ± 0.5
Ce, remifentanil (ng/ml) 2.5 ± 1.2 3.0 ± 1.3* 3.1 ± 1.3* 3.2 ± 1.1* 3.3 ± 1.1*
MAP (mmHg) 82 ± 13 85 ± 13 84 ± 10* 81 ± 10* 83 ± 10*
HR (beats/min) 64 ± 11 65 ± 12 68 ± 12 65 ± 11 65 ± 11
BT (°C) 36.0 ± 0.4 35.9 ± 0.4 35.9 ± 0.4 35.8 ± 0.4 35.8 ± 0.4
CVP (mmHg) 6 ± 3 7 ± 3 7 ± 3 7 ± 4 7 ± 3
CI (l/min/m) 2.6 ± 0.7 2.7 ± 0.7 2.8 ± 0.9 2.8 ± 0.8 2.9 ± 0.8
Ppeak (cmH2O) 19 ± 2 21 ± 3 23 ± 3 23 ± 3 23 ± 3
PaCO2 (mmHg) 42 ± 5 44 ± 5 45 ± 5 44 ± 5 44 ± 5
Arterial blood pH 7.4 ± 0.0 7.4 ± 0.0 7.4 ± 0.0 7.4 ± 0.0 7.4 ± 0.0
Base excess (mmol/l) 2.5 ± 1.9 2.3 ± 2.0 2.2 ± 2.0 2.0 ± 2.0 2.0 ± 1.9
TLV two-lung ventilation, OLV one-lung ventilation, Ce effect-site concentration, MAP mean arterial pressure, HR heart rate, BT body temperature, CVP central ven-
ous pressure, CI cardiac index, Ppeak peak airway pressure, PaCO2 arterial partial pressure of carbon dioxide. Values are means (SD)
* p <0.05 between the groups
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OLV levels at 60 min. On the other hand, arterial oxy-
genation was relatively well maintained during propofol
anesthesia throughout the study. None of the time
points during OLV indicated a lower PaO2 compared to
pre-OLV state in the propofol group.
One explanation for our results is that more vasodilation
induced by desflurane anesthesia would have attenuated
any protective effect of HPV during alveolar hypoxemia,
thus decreased systemic PaO2 in the desflurane group com-
pared to the propofol group. This is partially supported by
significantly lower arterial blood pressure despite the lesser
use in remifentanil during desflurane anesthesia compared
to propofol anesthesia in the present study (Table 2).
Significant drop in MAP during desflurane anesthesia com-
pared to propofol anesthesia also has been reported in pre-
vious animal study (66 vs. 103 mmHg), in which the effect
of anesthetics (desflurane vs. propofol) on arterial oxygen-
ation during OLV was evaluated [3].
Previously, an attempt to inhibit HPV by infusing the
potent vasodilator sodium nitroprusside (SNP) during
OLV has failed to show significant changes in pulmonary
vascular resistance (PVR), shunt fraction, or arterial oxy-
genation [29]. However, only seven patients were used to
evaluate the effect of administering SNP on HPV, by
measuring related parameters only once during OLV, be-
fore the surgery commenced. Moreover, there was no
time window from drug administration to measurement
of the variables, or duration of drug infusion to reach
the predefined goal (25% decrease in MAP), as presented
by the authors. Although vasodilation induced by SNP
decreased PVR (166 ± 23–131 ± 22 dynes/s/cm5) and
PaO2 (285 ± 42–225 ± 47 mmHg) in that study, the
decreases were not significant. Therefore, further investi-
gations may be needed.
Decreases in PaO2 and use of lung recruitment ma-
neuvers during OLV were observed in three patients that
received desflurane, while no cases were observed in the
propofol group. During the events, the lowest PaO2
levels under FIO2 of 1.0 were 60, 69, and 87 mmHg,
respectively. All episodes occurred after 30 min follow-
ing initiation of OLV. In the last case, the degree of
hypoxemia was not severe; however, the attending
anesthesiologist decided to provide rescue treatment and
proceed with OLV for the remainder of the surgical pro-
cedure. Similar events have been reported in previous
animal studies comparing desflurane and propofol dur-
ing in vivo OLV [3]. In this previous study, 3 of 10 pigs
showed oxygen desaturation < 90% during OLV with
desflurane anesthesia, while no cases were observed in
the group receiving propofol. Although there were no
further complications after desaturation in our study,
these results suggest that desflurane anesthesia for OLV
could result in deterioration of oxygenation especially in
subjects with under-reserved pulmonary function.
In the current study, blood pressure was managed
using adjustment of remifentanil infusion according to
the hemodynamic changes during the surgical proced-
ure. We tried to use anesthetic techniques relevant to
real clinical practice. It is clearly reflected in the lower
use of remifentanil in the desflurane group mainly due
to the sustained lower blood pressure in this group com-
pared to the propofol group. In a previous study in-
vestigated the effects of different concentrations of
remifentanil during OLV, no differences in PaO2 were
Fig. 2 Arterial oxygenation during desflurane-remifentanil vs. propofol-remifentanil anesthesia for one-lung ventilation. Data points are mean; error
bars are SD. PaO2 during OLV was lower in the desflurane group than the propofol group. During desflurane anesthesia, PaO2 was significantly lower
at 15, 30, and 45 min of OLV compared to the TLV state. PaO2, arterial partial pressure of oxygen; TLV, two-lung ventilation; OLV, one-lung ventilation;
OLV15, 15 min of OLV; OLV30, 30 min of OLV; OLV45, 45 min of OLV; OLV60, 60 min of OLV. * p <0.01 between the two groups during OLV period
(linear mixed model). # Adjusted p <0.01 when compared to the TLV state in the desflurane group (linear mixed model with Bonferroni’s correction)
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observed despite the significantly different blood pres-
sures [30]. Therefore, we considered that the observed
difference in PaO2 may not the consequence of the
difference in remifentanil use between the two groups
in this study.
Although a significant difference in PaO2 was detected
between the groups (170 vs. 202 mmHg at 30 min of
OLV in the desflurane vs. propofol group, respectively;
p = 0.039), the difference may be clinically irrelevant to
the anesthesiologist who is managing oxygenation in pa-
tients undergoing OLV. In this trial, we used a FIO2 of
1.0 throughout the OLV period with the expectation that
it would better distinguish the difference in oxygenation
between the groups [31]. A clinically significant differ-
ence in PaO2 may have been found between the two
groups if a lower FIO2 had been used.
In some studies, desflurane showed relatively con-
served vascular resistance compared to sevoflurane [32].
In other studies, desflurane has shown more vasodilatory
effect among inhalational anesthetics [11–14]. Although
no differences were observed in oxygenation between
sevoflurane and propofol anesthesia during OLV in several
previous studies [8–10], desflurane, even as balanced
anesthesia, showed more impaired oxygenation during
OLV compared with propofol anesthesia in the present
study. However, we did not compare the two popular in-
hales, sevoflurane vs. desflurane, in the present trial. Fur-
ther studies are required for comparison of effects of two
commonly used volatile anesthetics.
The following limitations should be considered when
interpreting our results. First, we did not measure the pul-
monary shunt fraction, perfusion or the extent of pulmon-
ary vasoconstriction in each isolated lung during surgery,
which could have explained the effects of the anesthetic
on pulmonary circulation, arteriovenous shunt fraction, or
the degree of ventilation/perfusion mismatch. Therefore,
it is difficult to conclude that there were any effects of the
anesthetics on the role of HPV during OLV from these re-
sults. Second, we did not fix the dose of desflurane, propo-
fol, or remifentanil during this study. Instead, they were
titrated by attending anesthesiologists in charge according
to anesthetic depth (BIS) or hemodynamic values. There-
fore, our results do not reflect the effect of any specific
anesthetic dose. Third, although we fixed FIO2 at 1.0 dur-
ing OLV in both groups, minimal loss of inspired oxygen
in the desflurane group was inevitable due to the volume
of inhaled anesthetic. However, the present anesthetic
protocol was based on the general practice of the in-
stitution. Thus, these results should be interpreted in the
context of a thoracic surgery anesthesia practice using in-
halational and/or intravenous anesthetics. The FIO2 or
concentration of inhalational anesthetics could be adjusted
according to the clinical setting. Fourth, the cardiac index
used in this study was calculated based on non-externally
calibrated pulse contour analysis, which may be less pre-
cise than pulmonary or transpulmonary thermodilution
methods. Therefore, this may have obscured the interpret-
ation of the effects of cardiac output on HPV. Finally, the
dose of desflurane administered during the study was 1.0–
1.1 MAC. This dosage may seem rather high for a bal-
anced anesthesia protocol, reflecting the lower MAP and
less use of remifentanil in the desflurane group compared
to those in the propofol group. However, in real clinical
situation, anesthesiologist continuously changes the dose
of anesthetics according to the patient’s responses, and we
believe that the results of our study may be more useful in
the clinical practice.
Conclusions
In conclusion, oxygenation under desflurane-remifentanil
balanced anesthesia was lower than that under propofol-
remifentanil TIVA during OLV for video-assisted thoraco-
scopic surgery. In patients who develop hypoxemia during
OLV with inhalational anesthetics, change anesthetics to
an intravenous agent should be considered.
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